CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 281 enrolled
Drug / intervention
BMS-986253 +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03400332
NCT03400332Phase 2Completed
CompareCT.gov

A Phase 1/2 Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers

Bristol-Myers Squibb·interventional·Posted Jan 17, 2018·Updated Feb 24, 2026

In Brief

A Phase 2 clinical trial evaluating BMS-986253, Nivolumab, and 2 other interventions for Cancer and Melanoma. Completed, enrolled 281 participants across 72 sites in 12 countries.

Detailed Summary

The purpose of this study is to investigate experimental medication BMS-986253 in combination with Nivolumab or Nivolumab plus Ipilimumab in participants with advanced cancers.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCancer, Melanoma
CountriesAustralia, Belgium, Canada, France, Germany, Italy, Poland, Spain, Sweden, Switzerland, United Kingdom, United States
Collaborators--

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedJan 17, 2018
Enrollment StartFeb 12, 2018
Primary CompletionApr 26, 2024
Study CompletionDec 4, 2025
TodayJul 2, 2026
Enrollment to primary: 6.2 yearsPosted 8.5 years ago

Interventions

BMS-986253drug

Specified dose on specified days

Nivolumabbiological

Specified dose on specified days

Ipilimumabbiological

Specified dose on specified days

Placeboother

Specified dose on specified days